PLRX
Pliant TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
PLRX vs peer average
95/100
PLRX vs. peer average (A vs. D)
Grade spread
A 1 · C 3 · D 2 · F 4
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
BCAX is the first available peer comparator.
TGF-β and pembrolizumab mechanism comparator, though its more advanced first-line head-and-neck program serves a different population. It is not a direct valuation peer. [Bicara company update](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-first-quarter-2026-financial-results)
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
PLRX
Pliant Therapeutics
BCAX
Bicara Therapeutics
Grade
A
A
Momentum
96
7
Value
57
41
Sentiment
74
100
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs BCAX
PLRX / BCAX
Grade Position
Above peers
PLRX vs. peer average (A vs. D)
95/100
Momentum
96
PLRXValue
57
PLRXSentiment
74
BCAXRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs PLRX
BCAX is the first peer returned for this comparison set.